Mantle Cell Lymphoma Clinical Trials

A listing of 51 Mantle Cell Lymphoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Mantle Cell Lymphoma

1 - 12 of 51

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 51 active clinical trials seeking participants for Mantle Cell Lymphoma research studies. The states with the highest number of trials for Autism participants are Illinois, New York, California and Washington.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Healthy Volunteer Trials

Recruiting

Healthy volunteer trials near you are looking for participants to help push medical research forward. Click through to learn more!

Conditions:

Healthy

Healthy Volunteers

Learn More

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

NCT04116437

Recruiting

The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment, by comparing intolerance to adverse event profile as assessed by the recurrence and the change in severity of adverse events.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/24/2024

Locations: Arizona Oncology Associates, Pc Hope, Tucson, Arizona +23 locations

Arizona Oncology Associates, Pc Hope, Tucson, Arizona

Rocky Mountain Cancer Centers (Williams) Usor, Aurora, Colorado

Christiana Care, Newark, Delaware

Scri Florida Cancer Specialists South, Fort Myers, Florida

Scri Florida Cancer Specialists North, Saint Petersburg, Florida

Healthcare Research Network Iii, Llc, Tinley Park, Illinois

Minnesota Oncology Burnsville Clinic, Burnsville, Minnesota

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Summit Medical Group, Florham Park, New Jersey

Morristown Medical Center, Morristown, New Jersey

Clinical Research Alliance, Inc, Westbury, New York

Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene, Oregon

St Lukes University Health Network, Bethlehem, Pennsylvania

Abington Hematology Oncology Associates, Horsham, Pennsylvania

Tennessee Oncology, Pllc Nashville, Nashville, Tennessee

Texas Oncology Amarillo, Amarillo, Texas

Baylor Research Institute, Dallas, Texas

Texas Oncology McAllen South Second Street, McAllen, Texas

Texas Oncology Tyler Longview, Tyler, Texas

Us Oncology Virginia Cancer Specialists, Pc, Fairfax, Virginia

Virginia Oncology Associates Hampton, Virginia Beach, Virginia

Fred Hutchinson Cancer Research Center, Seattle, Washington

Medical Oncology Associates, Spokane, Washington

Ssm Health Cancer Care Dean Medical Center, Madison, Wisconsin

Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia

Learn More ›

Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

NCT05471843

Recruiting

The study consists of two parts. Part 1 determines the safety and tolerability of BGB-11417 (sonrotoclax) monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the recommended Phase 2 dose with recommended ramp-up schedule from Part 1.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/24/2024

Locations: University of Alabama At Birmingham Hospital, Birmingham, Alabama +104 locations

University of Alabama At Birmingham Hospital, Birmingham, Alabama

Medstar Georgetown University Hospital, Washington, District of Columbia

Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana

Des Moines Oncology Research Association, Des Moines, Iowa

Tulane Cancer Center, New Orleans, Louisiana

Luminis Health Anne Arundel Medical Center, Annapolis, Maryland

Maryland Oncology Hematology, Pa, Columbia, Maryland

University of Missouri Hospital, Ellis Fischel Cancer Center, Columbia, Missouri

Nebraska Cancer Specialists, Grand Island, Nebraska

Dartmouth Cancer Center, Lebanon, New Hampshire

Hackensack University Medical Center, Hackensack, New Jersey

Novant Health Hematology Charlotte, Charlotte, North Carolina

The University of Texas Md Anderson Cancer Center, Houston, Texas

Northwest Medical Specialties, Puyallup, Washington

Hospital Aleman, Ciudad Autonoma de Buenos Aires, Not set

Az Sint Jan Brugge, Brugge, Not set

Universitair Ziekenhuis Gent, Gent, Not set

University Hospitals Leuven, Leuven, Not set

AZ DELTA, Roeselare, Not set

Hospital Erasto Gaertner, Curitiba, Not set

Hospital Mae de Deus, Porto Alegre, Not set

Hospital Das Clinicas Da Faculdade de Medicina de Ribeirao Preto Usp, Ribeirao Preto, Not set

Oncoclinicas Rio de Janeiro Sa, Rio de Janeiro, Not set

Instituto Americas Ensino, Pesquisa E Inovacao, Rio de Janeiro, Not set

Hospital Sao Rafael (Rede Dor), Salvador, Not set

Hospital Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Not set

Instituto Dor de Pesquisa E Ensino Sao Paulo, Sao Paulo, Not set

Accamargo Cancer Center, Sao Paulo, Not set

Hcfmusp Servico de Hematologia, Hemoterapia E Terapia Celular, Sao Paulo, Not set

Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, Sao Paulo, Not set

Qeii Health Science Center, Halifax, Nova Scotia

Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital, Hefei, Anhui

China Japan Friendship Hospital, Beijing, Beijing

Beijing Cancer Hospital, Beijing, Beijing

Beijing Friendship Hospital, Capital Medical University(Tongzhou), Beijing, Beijing

Fujian Cancer Hospital, Fuzhou, Fujian

Sun Yat Sen University Cancer Center, Guangzhou, Guangdong

Guangdong Provincial Peoples Hospital Huifu Branch, Guangzhou, Guangdong

Jiangmen Central Hospital, Jiangmen, Guangdong

The Tumor Hospital Affiliated to Guangxi Medical University, Nanning, Guangxi

Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou

Hainan General Hospital, Haikou, Hainan

Henan Cancer Hospital, Zhengzhou, Henan

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan

Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei

Hunan Cancer Hospital, Changsha, Hunan

Affiliated Hospital of Nantong University, Nantong, Jiangsu

The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi

Jiangxi Province Cancer Hospital, Nanchang, Jiangxi

Liaoning Cancer Hospital and Institute, Shenyang, Liaoning

General Hospital of Ningxia Medical University, Yinchuan, Ningxia

Shandong Cancer Hospital, Jinan, Shandong

The Affiliated Hospital of Qingdao University Branch West Coast, Qingdao, Shandong

Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi

West China Hospital, Sichuan University, Chengdu, Sichuan

Institute of Hematology and Hospital of Blood Disease, Tianjin, Tianjin

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin

The First Peoples Hospital of Kashgar, Kashgar, Xinjiang

Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang

Zhejiang Cancer Hospital, Hangzhou, Zhejiang

Centre Hospitalier Le Mans, Le Mans, Not set

Centre Hospitalier Universitaire Nantes Hotel Dieu, Nantes Cedex, Not set

Hopital Pitie Salpetriere Service Hematologie, Paris, Not set

Necker University Hospital, Paris, Not set

Chu Hopital Lyon Sud, PierreBenite, Not set

Chu Tours Hopital Bretonneau Service Pneumologie, Tours, Not set

Universitatsklinikum Dusseldorf, Dusseldorf, Not set

Universitatsklinikum Essen (Aor), Essen, Not set

Universitatsklinikum Schleswig Holstein, Campus Kiel, Kiel, Not set

Universitatsklinikum Koln, Innere Medizin I, Koeln, Not set

Assuta Ashdod Medical Center, Ashdod, Not set

Shaare Zedek Medical Center, Jerusalem, Not set

Hadassah En Karem Medical Center, Jerusalem, Not set

Rabin Medical Center, Petach Tikva, Not set

Sheba Medical Center, Tel Aviv, Not set

Sourasky Tel Aviv Medical Center, Tel Aviv, Not set

Irccs Istituto Tumori Giovanni Paolo Ii, Bari, Not set

Policlinico Sorsola Malpighi, Aou Di Bologna, Bologna, Not set

Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, Brescia, Not set

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst, Meldola, Not set

Aou Maggiore Della Carita, Novara, Not set

Uniwersyteckie Centrum Kliniczne, Gdansk, Not set

Pratia McM Krakow, Krakow, Not set

Samodzielny Publiczny Szpital Kliniczny Nr W Lublinie, Lublin, Not set

Narodowy Instytut Onkologii Im Marii Skodowskiej Curie Pastwowy Instytut Badawczy, Warszawa, Not set

Auxilio Mutuo Cancer Center, San Juan, Not set

Hospital Universitario Vall Dhebron, Barcelona, Not set

Institut Catala Dandoncologia, Barcelona, Not set

Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario Virgen Del Rocio, Sevilla, Not set

Ankara University Medical Faculty, Ankara, Not set

Dr Abdurrahman Yurtaslan Oncology Teaching and Research Hospital, Ankara, Not set

Gazi University, Ankara, Not set

Ondokuz Mayis University Medicine Faculty Hospital, Atakum Samsun, Not set

Bagcilar Medipol Mega Hospital, Istanbul, Not set

Vkv American Hospital, Istanbul, Not set

Ege University Medical Faculty, Izmir, Not set

Erciyes University School of Medicine, Kayseri, Not set

Kocaeli Universitesi Tip Fakultesi, Kocaeli, Not set

The Christie Hospital, Greater Manchester, Not set

Churchill Hospital Oxford University Hospital Nhs Trust, Headington, Not set

University College Hospital, London, Not set

Clatterbridge Cancer Centre, Wirral, Not set

Conditions: Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma

Learn More ›

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

NCT05529069

Recruiting

To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).

Gender:

All

Ages:

18 years and above

Trial Updated:

04/23/2024

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Mantle Cell Lymphoma, Non Hodgkin Lymphoma, Hematologic Malignancy

Learn More ›

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

NCT04223765

Recruiting

This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells targeted against the kappa light chain antibody on cancer cells. For this study, the anti-kappa light chain antibody has been changed so instead of floating free in the blood, a part of it is now joined to the T cells. Only the part of the antibody that sticks to the lymphoma cells is attached to the T cells. When an antibody is joined to a T cell in this way, it is called a chimeric receptor. The kappa light chain chimeric (combination) receptor-activated T cells are called ATLCAR.κ.28 cells. These cells may be able to destroy lymphoma cancer cells. They do not, however, last very long in the body so their chances of fighting the cancer are unknown. Previous studies have shown that a new gene can be put into T cells to increase their ability to recognize and kill cancer cells. A gene is a unit of DNA. Genes make up the chemical structure carrying your genetic information that may determine human characteristics (i.e., eye color, height and sex). The new gene that is put in the T cells in this study makes an antibody called an anti-kappa light chain. This anti-kappa light chain antibody usually floats around in the blood. The antibody can detect and stick to cancer cells called lymphoma cells because they have a substance on the outside of the cells called kappa light chains. The purpose of this study is to determine whether receiving the ATLCAR.κ.28 cells is safe and tolerable and learn more about the side effects and how effective these cells are in fighting lymphoma. Initially, the study doctors will test different doses of the ATLCAR.κ.28, to see which dose is safer for use in lymphoma patients. Once a safe dose is identified, the study team will administer this dose to more patients, to learn about how these cells affect lymphoma cancer cells and identify other side effects they might have on the body. This is the first time ATLCAR.κ.28 cells are given to patients with lymphoma. The Food and Drug Administration (FDA), has not approved giving ATLCAR.κ.28 as treatment for lymphoma. This is the first step in determining whether giving ATLCAR.κ.28 to others with lymphoma in the future will help them. Read Less

Gender:

All

Ages:

18 years and above

Trial Updated:

04/19/2024

Locations: Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

Conditions: Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma

Learn More ›

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297

Recruiting

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate. Cohort A: Participants with relapsed or refractory MCL rel... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/19/2024

Locations: Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska +101 locations

Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska

Banner MD Anderson Cancer Center - University Medical Center Phoenix-Medical Oncology ( Site 0036), Phoenix, Arizona

University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0008, Aurora, Colorado

Cancer Care Specialists of Illinois ( Site 0031), Decatur, Illinois

University of Kansas Medical Center-Division of Hematologic Malignancies and Cellular Therapeutics (, Fairway, Kansas

Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0007), Saint Matthews, Kentucky

Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010), Baltimore, Maryland

Tufts Medical Center ( Site 0024), Boston, Massachusetts

Massachusetts General Hospital ( Site 0018), Boston, Massachusetts

Dana-Farber Cancer Institute-Lymphoma ( Site 0026), Boston, Massachusetts

University of Michigan ( Site 0009), Ann Arbor, Michigan

Henry Ford Hospital ( Site 0035), Detroit, Michigan

Icahn School of Medicine at Mount Sinai ( Site 0023), New York, New York

Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0014), Fargo, North Dakota

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio

Avera Cancer Institute- Research ( Site 0011), Sioux Falls, South Dakota

Medical Oncology Associates, PS ( Site 0005), Spokane, Washington

University of Wisconsin Hospitals and Clinics-Carbone Cancer Center ( Site 0030), Madison, Wisconsin

MEDICAL COLLEGE OF WISCONSIN ( Site 0021), Milwaukee, Wisconsin

Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 1807), Natal, Rio Grande Do Norte

ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 1808), São Paulo, Sao Paulo

Instituto Nacional de Câncer - INCA-Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico HC1 (, Rio de Janeiro, Not set

Hospital Paulistano-Americas Oncologia ( Site 1805), Sao Paulo, Not set

BC Cancer Vancouver-Clinical Trials Unit ( Site 0201), Vancouver, British Columbia

The Moncton Hospital-Oncology ( Site 0211), Moncton, New Brunswick

QEII Health Sciences Centre - Victoria General Site ( Site 0213), Halifax, Nova Scotia

Lawson Health Research Institute - London Health Sciences Ce-London Regional Cancer Program ( Site 0, London, Ontario

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto, Ontario

Jewish General Hospital ( Site 0202), Montreal, Quebec

Allan Blair Cancer Centre-Care Services ( Site 0208), Regina, Saskatchewan

IC La Serena Research ( Site 1909), La Serena, Coquimbo

Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1907), Santiago, Region M. De Santiago

Clínica Alemana de Santiago ( Site 1903), Santiago, Region M. De Santiago

Beijing Cancer hospital ( Site 1200), Beijing, Beijing

Sun Yat-sen University Cancer Center ( Site 1201), Guangzhou, Guangdong

Zhujiang Hospital ( Site 1207), Guangzhou, Guangdong

Southern Medical University Nanfang Hospital ( Site 1202), Guangzhou, Guangdong

Henan Cancer Hospital-hematology department ( Site 1212), Zhengzhou, Henan

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1210), Wuhan, Hubei

Tongji Hospital Tongji Medical,Science & Technology ( Site 1221), Wuhan, Hubei

The First Affiliated Hospital of Soochow University-hematology department ( Site 1218), Suzhou, Jiangsu

The Affiliated Hospital of Xuzhou Medical College ( Site 1223), Xuzhou, Jiangsu

The First Affiliated Hospital of Nanchang University ( Site 1204), Nanchang, Jiangxi

Jiangxi Provincial Cancer Hospital ( Site 1213), Nanchang, Jiangxi

Jilin Province Tumor Hospital-oncology department ( Site 1220), Changchun, Jilin

Fudan University Shanghai Cancer Center ( Site 1208), Shanghai, Shanghai

West China Hospital of Sichuan University-Head and Neck Oncology ( Site 1206), Cheng Du, Sichuan

The First Affiliated Hospital, Zhejiang University ( Site 1211), Hangzhou, Zhejiang

Zhejiang Cancer Hospital ( Site 1214), Hangzhou, Zhejiang

Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0300), Brno, Brno-mesto

Fakultni nemocnice Ostrava-Klinika Hematoonkologie ( Site 0301), Ostrava, Moravskoslezsky Kraj

Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0302), Praha 2, Not set

North Estonia Medical Centre Foundation ( Site 0401), Tallinn, Harjumaa

Universitaetsklinikum Ulm ( Site 0502), Ulm, Baden-Wurttemberg

Universitaetsklinikum Koeln ( Site 0506), Köln, Nordrhein-Westfalen

St. James's Hospital ( Site 0600), Dublin, Not set

Emek Medical Center-Hematology Unit ( Site 0705), Afula, Not set

Soroka Medical Center-Hematology Department ( Site 0707), Be'er Sheva, Not set

Rambam Health Care Campus-Hematology and Bone Marrow Transplantation ( Site 0706), Haifa, Not set

Carmel Hospital ( Site 0709), Haifa, Not set

Hadassah Medical Center ( Site 0701), Jerusalem, Not set

Sheba Medical Center-Hemato Oncology ( Site 0700), Ramat Gan, Not set

IRCCS - AOU di Bologna-SSD: Diagnosi e terapie dei linfomi e delle sindromi linfoproliferative cron, Bologna, Emilia-Romagna

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 0804), Roma, Lazio

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0802), Rozzano, Milano

Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare -Azienda Ospedaliera Nazionale SS. Ant, Alessandria, Not set

National Hospital Organization Nagoya Medical Center ( Site 1108), Nagoya, Aichi

Hokkaido University Hospital ( Site 1104), Sapporo, Hokkaido

Tokai University Hospital- Isehara Campus ( Site 1100), Isehara, Kanagawa

Tohoku University Hospital ( Site 1106), Sendai-shi, Miyagi

Kindai University Hospital- Osakasayama Campus ( Site 1102), Osaka-sayama, Osaka

National Cancer Center Hospital ( Site 1103), Chuo-ku, Tokyo

Japanese Foundation for Cancer Research ( Site 1101), Koto, Tokyo

Kyushu University Hospital ( Site 1105), Fukuoka, Not set

Okayama University Hospital ( Site 1107), Okayama, Not set

Seoul National University Hospital ( Site 1300), Seoul, Not set

Samsung Medical Center ( Site 1301), Seoul, Not set

INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 1700), Lima, Not set

Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumat-Oddiał Hematologii Ogólnej ( Site 1008), Łódź, Lodzkie

Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologiczny ( Site 1006), Lublin, Lubelskie

Pratia MCM Krakow ( Site 1001), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( S, Warszawa, Mazowieckie

Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA w Olsztynie-Oddzial Kliniczny Hematologii ( Sit, Olsztyn, Warminsko-mazurskie

Champalimaud Foundation ( Site 2002), Lisbon, Lisboa

2CA BRAGA ( Site 2001), Braga, Not set

Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 2000), Porto, Not set

National Cancer Centre Singapore ( Site 1500), Singapore, Central Singapore

Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 4003), L'Hospitalet Del Llobregat, Barcelona

Clinica Universidad de Navarra ( Site 4005), Pamplona, Navarra

Hospital Universitari Vall d'Hebron ( Site 4004), Barcelona, Not set

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca-Hematology ( S, Salamanca, Not set

Skånes Universitetssjukhus Lund ( Site 5000), Lund, Skane Lan

Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 5002), Uppsala, Uppsala Lan

Sahlgrenska Universitetssjukhuset ( Site 5003), Gothenburg, Vastra Gotalands Lan

Mega Medipol-Hematology ( Site 6009), Stanbul, Istanbul

Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 6001), Ankara, Not set

Trakya University ( Site 6005), Edirne, Not set

Ege Universitesi Hastanesi ( Site 6002), İzmir, Not set

Ondokuz Mayıs Universitesi-Oncology department ( Site 6004), Samsun, Not set

The Royal Cornwall Hospital-Haematology ( Site 7006), Truro, Cornwall

University College London Hospital ( Site 7001), London, England

The Churchill Hospital ( Site 7002), Oxford, Oxfordshire

Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma

Learn More ›

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

NCT03246906

Recruiting

This randomized phase II trial includes a blood stem cell transplant from an unrelated donor to treat blood cancer. The treatment also includes chemotherapy drugs, but in lower doses than conventional (standard) stem cell transplants. The researchers will compare two different drug combinations used to reduce the risk of a common but serious complication called "graft versus host disease" (GVHD) following the transplant. Two drugs, cyclosporine (CSP) and sirolimus (SIR), will be combined with ei... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/18/2024

Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Hematologic and Lymphocytic Disorder, Blastic Plasmacytoid Dendritic Cell Neoplasm

Learn More ›

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NCT06054776

Recruiting

This phase II trial studies the side effects of acalabrutinib, obinutuzumab, and glofitamab and how well they work together for treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/16/2024

Locations: City of Hope Medical Center, Duarte, California

Conditions: Mantle Cell Lymphoma

Learn More ›

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

NCT06004167

Recruiting

Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy. This research is being done to see if a new radiation therapy administration schedule will positively impact the logistics, time, cost, and side effects of radiation therapy. In this research study, participants will receive radiation therapy once weekly for 5 weeks. This i... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/12/2024

Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations

Conditions: Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma, Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma

Learn More ›

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT05976763

Recruiting

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used... Read More

Gender:

All

Ages:

60 years and above

Trial Updated:

04/08/2024

Locations: City of Hope Comprehensive Cancer Center, Duarte, California +137 locations

City of Hope Comprehensive Cancer Center, Duarte, California

City of Hope at Irvine Lennar, Irvine, California

Cedars Sinai Medical Center, Los Angeles, California

Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut

Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut

Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury, Connecticut

Smilow Cancer Hospital Care Center at Greenwich, Greenwich, Connecticut

Smilow Cancer Hospital Care Center - Guilford, Guilford, Connecticut

Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut

Yale University, New Haven, Connecticut

Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut

Smilow Cancer Hospital Care Center at Long Ridge, Stamford, Connecticut

Smilow Cancer Hospital-Torrington Care Center, Torrington, Connecticut

Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut

Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut

Smilow Cancer Hospital Care Center - Waterford, Waterford, Connecticut

Helen F Graham Cancer Center, Newark, Delaware

Medical Oncology Hematology Consultants PA, Newark, Delaware

Augusta University Medical Center, Augusta, Georgia

Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho

Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho

Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho

Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho

Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho

Kootenai Cancer Clinic, Sandpoint, Idaho

Illinois CancerCare-Bloomington, Bloomington, Illinois

Illinois CancerCare-Canton, Canton, Illinois

Illinois CancerCare-Carthage, Carthage, Illinois

Carle at The Riverfront, Danville, Illinois

Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois

Decatur Memorial Hospital, Decatur, Illinois

Illinois CancerCare-Dixon, Dixon, Illinois

Carle Physician Group-Effingham, Effingham, Illinois

Crossroads Cancer Center, Effingham, Illinois

Illinois CancerCare-Eureka, Eureka, Illinois

Illinois CancerCare-Galesburg, Galesburg, Illinois

Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois

Illinois CancerCare-Macomb, Macomb, Illinois

Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois

Cancer Care Center of O'Fallon, O'Fallon, Illinois

Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois

Illinois CancerCare-Pekin, Pekin, Illinois

Illinois CancerCare-Peoria, Peoria, Illinois

Illinois CancerCare-Peru, Peru, Illinois

Illinois CancerCare-Princeton, Princeton, Illinois

Memorial Hospital East, Shiloh, Illinois

Southern Illinois University School of Medicine, Springfield, Illinois

Springfield Clinic, Springfield, Illinois

Memorial Medical Center, Springfield, Illinois

Carle Cancer Center, Urbana, Illinois

Illinois CancerCare - Washington, Washington, Illinois

Northwest Cancer Center - Main Campus, Crown Point, Indiana

Northwest Oncology LLC, Dyer, Indiana

Northwest Cancer Center - Hobart, Hobart, Indiana

Saint Mary Medical Center, Hobart, Indiana

Saint Catherine Hospital, Indianapolis, Indiana

The Community Hospital, Munster, Indiana

Women's Diagnostic Center - Munster, Munster, Indiana

Northwest Cancer Center - Valparaiso, Valparaiso, Indiana

Mary Greeley Medical Center, Ames, Iowa

McFarland Clinic - Ames, Ames, Iowa

McFarland Clinic - Boone, Boone, Iowa

Mercy Medical Center - Des Moines, Des Moines, Iowa

McFarland Clinic - Trinity Cancer Center, Fort Dodge, Iowa

University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa

McFarland Clinic - Jefferson, Jefferson, Iowa

McFarland Clinic - Marshalltown, Marshalltown, Iowa

University of Kansas Cancer Center, Kansas City, Kansas

University of Kansas Cancer Center-Overland Park, Overland Park, Kansas

University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas

Alliance for Clinical Trials in Oncology, Boston, Massachusetts

Saint Joseph Mercy Hospital, Ann Arbor, Michigan

Saint Joseph Mercy Brighton, Brighton, Michigan

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton, Michigan

Saint Joseph Mercy Canton, Canton, Michigan

Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton, Michigan

Saint Joseph Mercy Chelsea, Chelsea, Michigan

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea, Michigan

Beaumont Hospital - Farmington Hills, Farmington Hills, Michigan

Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan

Genesee Hematology Oncology PC, Flint, Michigan

Genesys Hurley Cancer Institute, Flint, Michigan

Hurley Medical Center, Flint, Michigan

Trinity Health Saint Mary Mercy Livonia Hospital, Livonia, Michigan

Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan

William Beaumont Hospital-Royal Oak, Royal Oak, Michigan

William Beaumont Hospital - Troy, Troy, Michigan

Huron Gastroenterology PC, Ypsilanti, Michigan

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti, Michigan

Sanford Joe Lueken Cancer Center, Bemidji, Minnesota

Saint Francis Medical Center, Cape Girardeau, Missouri

Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri

University of Kansas Cancer Center - North, Kansas City, Missouri

University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri

University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Siteman Cancer Center-South County, Saint Louis, Missouri

Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri

Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri

Mercy Hospital Springfield, Springfield, Missouri

Community Hospital of Anaconda, Anaconda, Montana

Billings Clinic Cancer Center, Billings, Montana

Bozeman Deaconess Hospital, Bozeman, Montana

Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana

Kalispell Regional Medical Center, Kalispell, Montana

Community Medical Hospital, Missoula, Montana

Nebraska Medicine-Bellevue, Bellevue, Nebraska

Nebraska Medicine-Village Pointe, Omaha, Nebraska

University of Nebraska Medical Center, Omaha, Nebraska

Roswell Park Cancer Institute, Buffalo, New York

University of Rochester, Rochester, New York

Wilmot Cancer Institute at Webster, Webster, New York

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Sanford Bismarck Medical Center, Bismarck, North Dakota

Sanford Broadway Medical Center, Fargo, North Dakota

Sanford Roger Maris Cancer Center, Fargo, North Dakota

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma

Providence Newberg Medical Center, Newberg, Oregon

Saint Alphonsus Medical Center-Ontario, Ontario, Oregon

Providence Willamette Falls Medical Center, Oregon City, Oregon

Providence Portland Medical Center, Portland, Oregon

Providence Saint Vincent Medical Center, Portland, Oregon

Rhode Island Hospital, Providence, Rhode Island

Smilow Cancer Hospital Care Center - Westerly, Westerly, Rhode Island

Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota

Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota

Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah

Swedish Cancer Institute-Edmonds, Edmonds, Washington

Swedish Cancer Institute-Issaquah, Issaquah, Washington

Swedish Medical Center-First Hill, Seattle, Washington

Medical College of Wisconsin, Milwaukee, Wisconsin

ProHealth D N Greenwald Center, Mukwonago, Wisconsin

Froedtert and MCW Moorland Reserve Health Center, New Berlin, Wisconsin

ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin

UW Cancer Center at ProHealth Care, Waukesha, Wisconsin

Conditions: Mantle Cell Lymphoma

Learn More ›

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

NCT06014762

Recruiting

Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

Gender:

All

Ages:

18 years and above

Trial Updated:

04/05/2024

Locations: University of California San Diego, La Jolla, California +9 locations

Conditions: Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Chronic Lymphocytic Leukemia

Learn More ›

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

NCT05724121

Recruiting

Background: Bruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm. This can cause sudden death. In this natural history study, researchers want to learn how BTKi affects the heart. Objective: To identify and monitor the effects of BTKi on the heart. Eligibility: People aged 18 and older currently receiving or planning to receive BTKi or venetoclax. Design: Participants who h... Read More

Gender:

All

Ages:

Between 18 years and 110 years

Trial Updated:

04/04/2024

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia, Mantle Cell Lymphoma, Sudden Cardiac Death, Cardiac Arrhythmias, Hematologic Malignancies

Learn More ›

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT05544019

Recruiting

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-1505.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/03/2024

Locations: Banner Health - MD Anderson Cancer Center, Gilbert, Arizona +14 locations

Conditions: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma

Learn More ›

1 - 12 of 51